EMBLA Embla Medical hf.
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.…
Industry Peers
Medical DevicesKey Statistics
About Embla Medical (CPH: EMBLA)
›
Embla Medical (CPH: EMBLA) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 4,500 employees.
The shares were at 27.45 DKK on 19 November 2026, down 19.5% over 52 weeks. Its 52-week range is 25.00 DKK to 37.90 DKK: the price is 27.6% below the high and 9.8% above the low.
At a market capitalisation of 11.67B DKK, it trades at 19.3 times trailing earnings and 15.8 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a discount of 25% for EMBLA.
Embla Medical reports return on equity of 9.4%, an operating margin of 13.6% and revenue up 5.4% year over year.
Its debt exceeds its cash by 414.44M USD, a debt-to-equity ratio of 0.61. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 31.90 DKK is 16.2% above the current price. The next earnings report is expected on 2 February 2027.